A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Inclusion Criteria

• •Male or female patients \>= 18 years old
• •Patients with either unresectable Stage IIIc or Stage IV metastatic melanoma positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF, as determined by results of cobas® 4800 BRAF V600 mutation test or a DNA sequencing method, and who have no acceptable standard treatment options
• •Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
• •Life expectancy \>= 12 weeks
• •Full recovery from the effects of any major surgery or significant traumatic injury within 14 days prior to the first dose of study treatment
• •Adequate hematologic and end organ function
• •Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use two effective methods of contraception
• •Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential